Discovery of Novel 1,2,3-triazole Derivatives as IDO1 Inhibitors

Indoleamine 2,3-dioxygenase 1 (IDO1) has received much attention as an immunomodulatory enzyme in the field of cancer immunotherapy. While several IDO1 inhibitors have entered clinical trials, there are currently no IDO1 inhibitor drugs on the market. To explore potential IDO1 inhibitors, we designe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Xixi, Gong, Xiaoqing, Mao, Longfei, Zhao, Jie, Yang, Jianxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695734/
https://www.ncbi.nlm.nih.gov/pubmed/36355488
http://dx.doi.org/10.3390/ph15111316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695734/
https://www.ncbi.nlm.nih.gov/pubmed/36355488
http://dx.doi.org/10.3390/ph15111316

Ejemplares similares